We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+39.45%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$1.29B
AUM Growth
+$497M
Cap. Flow
+$278M
Cap. Flow %
21.56%
Top 10 Hldgs %
61.71%
Holding
54
New
8
Increased
22
Reduced
6
Closed
11

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$51.1M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$44.7M
3
IMMU
Immunomedics Inc
IMMU
+$42.4M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$39.4M
5
PCRX icon
Pacira BioSciences
PCRX
+$34M

Top Sells

Rank Stock Value
1
KITE
Kite Pharma, Inc.
KITE
+$43.2M
2
TSRO
TESARO, Inc.
TSRO
+$25.5M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$17.1M
4
AERI
Aerie Pharmaceuticals
AERI
+$12.1M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 67.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
51
DELISTED
Aerie Pharmaceuticals
AERI
– –
-230,842
Closed -$12.1M
MDCO
52
CALL
DELISTED
Medicines Co
MDCO
– –
-200,000
Closed -$50K
NDRM
53
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-44,516
Closed -$1.33M
1 2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q3 2017 Portfolio in Review

As of Q3 2017, Avoro Capital Advisors held 54 positions worth $1.29B, up 63% from $792M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Avoro Capital Advisors deployed $278M of net new capital in Q3 2017, opening 8 new positions and adding to 22 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 3,516,100 shares worth $44.6M.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 65% a quarter earlier.

On the sell side, the largest reduction was Kite Pharma, Inc., an estimated $43.2M trimmed.

  • Avoro Capital Advisors's largest Q3 2017 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 3,516,100 shares worth $44.6M.
  • Avoro Capital Advisors added most to Clovis Oncology, Inc. in Q3 2017, an estimated $51.1M increase.
  • Avoro Capital Advisors's biggest Q3 2017 reduction was Kite Pharma, Inc., cutting an estimated $43.2M.
  • Avoro Capital Advisors fully exited Acadia Pharmaceuticals in Q3 2017, selling an estimated $17.1M.
  • Avoro Capital Advisors's ten largest holdings make up 62% of its $1.29B portfolio in Q3 2017.
  • Avoro Capital Advisors opened 8 new positions and closed 11 in Q3 2017.
  • Avoro Capital Advisors's portfolio value rose 63% quarter-over-quarter to $1.29B.

Based on Avoro Capital Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.